Nuvonis Technologies

Providing the gene therapy & vaccine sector with excellent serum free Vero cell banks and one / two step purification technology.

[Ajit Johnson Nirmal @ajitjohnson_n]

Scientists have used CRISPR to alter the color, shape, and rigidity of butterfly wings. https://t.co/k0Y9ICckow

[Esco Lifesciences Group @EscoLifesci]

Thank you for visiting us at ESHRE! We have received overwhelming positive response especially on our AuVis Vitrification System prototype.

We hope that you enjoyed the conference as much as we did. We are looking forward to seeing you all again soon. #ESHRE

[Zack Schildhorn @zacktrak]

@awealthofcs More people in U.S. have Tattoos than iPhones. Removal has several current issues: 1) many treatments required 2) doesn’t work on all ink colors 3) on darker skin it destroys pigment 4)painful. Have investigated (and invested) @Lux_Capital

[Gil Dibner @gdibner]

New VC firm out of stealth today. Angular Ventures. Early stage. Enterprise. Deep Tech. European + Israeli companies with global (US) ambition. https://t.co/4bKEeki58b

[National Cancer Institute @theNCI]

What is CAR T-cell therapy? It involves changing a patient’s immune cells in the lab so they'll attack cancer cells. https://t.co/V8BAGQ6pyv #AACR18

[Nektar Therapeutics @NektarNews]

Dr. Lei Wang from Syndax Pharmaceuticals presents preclinical data on NKTR-214 + entinostat at #AACR18. Access the poster here: https://t.co/KdU9BTlwSj

[soria @jsoriamd]

A major theme for the future research in #Immunotherapy is Tissue-Specific Immunoregulation. Surprisingly we have very little data on organ-specific regulation of immunity. Very little such data at #AACR18
Check out this superb review by William Pao
https://t.co/F04e8BpvDC

[soria @jsoriamd]

analyses of more than 10,000 tumors identified six immune subtypes that
encompass multiple cancer types and are hypothesized to define immune response patterns impacting prognosis
https://t.co/HjKVJGVKWI

[Josh Berlin @BioPharmaJosh]

China biotechs must globalize product development to ensure ROI (given lower reimbursement in home market) - Fountain Medical Chairman Dan Zhang, Suzhou Founder's Club spring meeting

[soria @jsoriamd]

To all apologies for the link provided, this is the direct one
https://t.co/hjzaH13PZU
That being said this is truly a must read https://t.co/bjX7pWhTlk

[Labiotech.eu @Labiotech_eu]

It's raining money! Martin Münchbach shares his best #strategies for #fundraising 🤑 #bbbiotech #VentureCapital #startup
https://t.co/vu5xn0JgbS

[soria @jsoriamd]

Genetic aberrations in cancer cells dictate the immune contexture of tumors
A must read
https://t.co/EUU7ww3tPn

[Alban REMY @Alban_remy]

Harald Isemann chairman of @viennabiocenter is presenting their amazing campus to our @GotoGrow_London Life Science delegation @L_Pbusiness

[Josh Berlin @BioPharmaJosh]

Hong Kong is accelerating its plans, biotech listing rules will be finalized in April, 1st IPO applications in May - Michael Chan, HKEX #BIOASIA18

[BioWorld @BioWorld]

Remember that $133M deal Mirati Therapeutics signed with Beigene in January? At #BIOASIA18, Mirati's Christopher LeMasters says that, in light of the many many combo I-O trials underway, a key win was unlocking access to new trial populations in China.

[BioWorld @BioWorld]

The stars have aligned in the Hong Kong market, says Michael Chan, SVP of HKEX, with 3 pools of investors fueling liquidity: Western institutional investors, Asian investors inc. sovereign wealth, and mainland Chinese investors, unable to invest abroad, coming to HK #BIOASIA18

[BioWorld @BioWorld]

Zai Lab BD director Jonathan Wang said China's govt. is always trying new things with companies, wanting to see what works. Partnering with regulators, as Zai has done, is an important exercise in building trust, avoiding risk, he added. #BIOASIA18

[Novartis @Novartis]

#BreakingNews: Novartis licenses biomaterial systems from @Harvard for delivering cancer immunotherapy #NovartisNews

[BioWorld @BioWorld]

C-Bridge Capital managing director Tong Zhang, speaking at #BIOASIA18, says the firm has invested the majority of its current $400 million fund (almost x 2 with LP contributions) and is now raising a new fund.

[Nuvonis Technologies @Nuvonis_Tech]

About Immuno-Oncology News https://t.co/B8KVxlBsim